FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response:	s)														
1. Name and Address of Reporting Person * KIERNAN ROBERT J				2. Issuer Name and Ticker or Trading Symbol Global Medical REIT Inc. [GMRE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 2 BETHESDA METRO CENTER, SUITE 440				3. Date of Earliest Transaction (Month/Day/Year) 03/05/2019						_x	X Officer (give title below) Other (specify below) Chief Financial Officer					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
	SDA, MD 2															
(City	y)	(State)	(Zip)			Tabl	e I - 1	Non-Dei	rivati	ve Securiti	es Acquirec	l, Dispose	d of, or Ben	eficially Owi	ned	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, any (Month/Day/Ye		(Instr. 8)		(A)		curities Accor Disposed	of (D) Ow Tra			ed :	Form:	7. Nature of Indirect Beneficial Ownership	
						Code	V	Amo	unt (A) or	Price			((I) (Instr. 4)	(IIIsti. 4)	
Reminder:	Report on a s	separate line for eac	h class of securities	s beneficial	lly ov	vned dire	ectly	_	-	who rospo	nd to the o	collection	of inform	ation	SEC	1474 (9-02)
								conta	ined	in this fo		required	l to respon	d unless th		14/4 (9-02)
			Table II -							d of, or Ber ertible secu	neficially O	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, i any (Month/Day/Year	if Transaction Code Sur) (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Underly Securities (Instr. 3 and	ing		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners. Form of Derivati Security Direct (or Indirect)	Ownersh (Instr. 4) D) ect	
				Code	V	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
LTIP Unit (Right to Buy)	<u>(2)</u>	03/05/2019(3)		A		13,275 (3)		<u>(2</u>)	(2)	Common Stock	13,275	\$ 0	50,670	D	
LTIP Unit (Right to Buy)	(2)	03/05/2019(4)		A		6,356 (4)		(2)	(2)	Common Stock	6,356	\$ 0	57,026	D	
LTIP Unit (Right to Buy)	(2)	03/05/2019 ⁽⁵⁾		A		3,250 (5)		(2))	(2)	Common Stock	3,250	\$ 0	60,276	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
KIERNAN ROBERT J 2 BETHESDA METRO CENTER, SUITE 440 BETHESDA, MD 20814			Chief Financial Officer				

Signatures

/s/ Robert J. Kiernan	03/07/2019			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 5, 2019 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2018 and 50% of the LTIP Units will vest on March 5, 2020, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
- (2) As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
- (3) Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on April 12, 2018
- LTIP Units vest in equal one-third installments on March 5 of 2020, 2021 and 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
- (5) 50% of the LTIP Units vested at issuance and the remaining will vest on March 5, 2020 pursuant to the grant award agreement stipulations.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.